Axial Spondyloarthritis Disease Activity Cutoffs at Golimumab Initiation in the French GO-PRACTICE Study: Parallels With the German GO-NICE Study.

Axial Spondyloarthritis Disease Activity Cutoffs at Golimumab Initiation in the French GO-PRACTICE Study: Parallels With the German GO-NICE Study. J Rheumatol. 2020 Oct 15;: Authors: Goupille P, Harid N, Flipo RM Abstract Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disorder that includes both radiographic and nonradiographic entities1 International guidelines for axSpA management recommend nonsteroidal antiinflammatory drugs as the first line of treatment2,3. PMID: 33060324 [PubMed - as supplied by publisher]
Source: J Rheumatol - Category: Rheumatology Authors: Tags: J Rheumatol Source Type: research